Health
FDA Approves Scholar Rock's ISEMBYLD as First Muscle Targeted SMA Therapy
Scholar Rock won U.S. approval for ISEMBYLD, an antibody that blocks myostatin and becomes the first SMA treatment aimed at preserving muscle in patients already on SMN2 therapies.
TechQuire Daily Staff
/
9 hours, 59 minutes ago
/
7 min read